Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 272-342-0 | CAS number: 68814-89-1 A complex combination of hydrocarbons obtained as the extract from a solvent extraction of heavy paraffinic distillate.
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
Treated distillate aromatic extracts (TDAEs) are a further processing of distillate aromatic extracts (DAEs) in an attempt to reduce the amount of 3-7 ring PAC that is present. Since the treatment is mostly a selective reduction of PACs, the data from DAEs can serve as read across where treatment was insufficient and a significant amount of PACs still remain (≥ 3 wt% DMSO extractables as measured by IP-346). Where treatment was sufficient to reduce the 3-7 ring PACs (<3 wt% DMSO extractables as measured by IP-346), the material is most similar to a lubricating base oil and it is this data that should be used for read across.
TDAEs (IP 346 ≥ 3 wt%)
In a read-across bioavailability toxicokinetics study in pregnant rats, three doses of 1000 mg/kg of radiolabelled 318 isthmus furfural extract (a distillate aromatic extract) was dermally administered on gestation days 10, 11, and 12 (Mobil 1989, Klimisch score = 4). Maternal tissues, blood, placentas, uteri, embryos, and yolk sacs were collected and analyzed for radioactivity on gestation day 13 following sacrifice. Urine, faeces, and cage wash was collected every 24 hours and also analyzed for radioactivity.
Dermal absorption of 14C-carbazole occurred more extensively than did 3H-benzo(a)pyrene over a 72 hour period. About 19.9% and 4.1% of the total applied of 14C-carbazole and 3H-benzo(a)pyrene, respectively, was dermally absorbed. Of the total absorbed dose of 14-C-carbazole, 2.1% was found in the maternal tissues and less than 0.01% was detected in the embryo. Of the total absorbed dose of 3H-benzo(a)pyrene 1.8% was detected in the maternal tissue and less than 0.01% was found in the embryo. 17.7% of 14C-carbazole was excreted in the urine and faeces over 72 hours. 2.3% of 3Hbenzo(a)pyrene was excreted in the urine and faeces over 72 hours.
Based on the bioavailability results, neither of the radiolabelled components of 318 isthmus furfural extract were found to selectively accumulate in the embryo.
Mutagenicity and carcinogenicity of a series of 39 petroleum oils, including several DAEs, were correlated with the content of 3-7 ring PACs. Further, the steady-state dermal penetration of PAC in long-term testing was also determined predominantly by PAC concentration. Although aromaticity and viscosity had a minimal effect on dermal penetration, neither was an important determinant of the carcinogenic potency.
Substances in this category are UVCBs; hence it is not possible to apply standard methodology for assessing absorption, distribution and metabolism. Relevant data for use in risk assessment are available for constituent compounds.
TDAEs (IP 346 < 3 wt%)
In a basic toxicokinetic study performed by Baldwin et al., (1992) hydrotreated treated white oil was mixed with the diet of male and female rats in concentrations of 0, 10, 100, 500, 1000, 5000, 10000, and 20000 ppm for a period of 13 weeks. After sacrifice, haematological, clinical chemistry, gross necropsy, tissue residue, and histopathological examinations were preformed. There were no mortalities or adverse effects associated with feeding the rats oleum-treated white oil. Treatment related effects were generally dose-related and more marked in females than in males. After 90 days of treatment moderate multifocal granulomatous changes in mesenteric lymph nodes and liver were observed. Oleum-treated oil caused a greater pathological response then hydrotreated white oil. The hydrotreated white oil (applicable to sufficiently refined hydrocarbons, IP 346 < 3%) is metabolized to the corresponding fatty acids of the same carbon chain length as the parent carbons, suggesting omega oxidation.
A toxicokinetics study performed by Albro et al. (1970) evaluated absorption of hydrocarbon mixtures (IP 346 <3%). Simple mixtures of aliphatic hydrocarbons were administered to rats by gastric intubation at dose levels of up to 500 mg/kg b.w. The percentage retention of the aliphatic hydrocarbons was inversely proportional to the number of carbon atoms and ranged from 60% for C14to 5% for C28compounds. The major site of absorption was found to be the small intestine.
A toxicokinetics study performed by Ebert et al. (1966) evaluated distribution of tritiated mineral oil (IP 346 <3%) administered orally and via i.p. injections. Male and female rats were dosed with 0.66 mL of radiolabelled mineral oil for thirty-one consecutive days. Radioactivity was measured in extracted tissues after sacrifice. Urine and faeces were collected and stored daily for radioactivity analysis. Results indicate that radioactivity is primarily found in liver, fat, kidney, brain, and spleen. Eighty percent of the tritiated mineral oil administered orally was not absorbed but rather excreted in the faeces two days after treatment. Only 11% of the total dose administered by i.p. injection was excreted in the faeces during the first 8 days of the study. About 8% of the radioactivity administered orally and via intraperitoneal injection was excreted in the urine during the week following drug administration. Both oral and i.p. routes of administration exhibited the same characteristics of absorption.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.